CERS vs CSL: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
CSL is the larger of the two ($14.90B market cap): the incumbent the market prices for continued execution (16.01x forward earnings, beta 0.78). CERS is the smaller challenger ($385.73M), actually pricier on forward earnings (127.33x): more room to run, but more to prove. If you believe CERS earns its premium (127.33x forward earnings, so the market expects more from it), CERS fits. If you believe in paying less for profit, CSL fits at 16.01x.
CERS vs CSL: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | CERS | CSL | What it tells you |
|---|---|---|---|
| Market cap | $385.73M | $14.90B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 127.33 | 16.01 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 1.85 | 0.78 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 22% of range | 65% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 5.09 | 10.37 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: CSL is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how CERS and CSL affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CERS and CSL share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CERS and CSL exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Cerus Corporation (CERS) do?
Cerus Corporation, based in Concord, California, makes the INTERCEPT Blood System, a technology that treats donated blood components so that viruses, bacteria, parasites and white blood cells cannot replicate. The process uses amotosalen, a compound that binds to DNA and RNA, activated by ultraviolet A light in a device called an illuminator. INTERCEPT is approved for platelets and plasma in the US and Europe and is used by blood centers in dozens of countries. Cerus sells the disposable treatment kits, which is where most revenue comes from, plus the illuminators. A second product, INTERCEPT Fibrinogen Complex (IFC), is made from pathogen-reduced plasma and used to control bleeding, mostly in US hospitals. The company also earns government contract revenue from BARDA, the US agency funding its red blood cell program.
What does Carlisle Companies Incorporated (CSL) do?
Carlisle Companies Incorporated (NYSE: CSL) is a diversified manufacturer that, after years of portfolio reshaping, has become a focused supplier of building-envelope products that make commercial and residential buildings more energy efficient. It operates through two segments: Carlisle Construction Materials (CCM), which makes single-ply roofing membranes (EPDM rubber, TPO, and PVC), polyiso insulation, and metal roofing and wall systems, and Carlisle Weatherproofing Technologies (CWT), which makes waterproofing, air and vapor barriers, sealants, spray polyurethane foam, coatings, and related moisture-protection products. The company earns most of its revenue from commercial construction, and within that, a large share comes from re-roofing (replacing aging roofs), which is more stable than new construction because roofs wear out on a predictable cycle regardless of the economy.
CERS vs CSL: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- CERS drivers: Platelet and plasma kit volume; INTERCEPT Fibrinogen Complex.
- CSL drivers: Commercial re-roofing replacement cycle; Margin expansion and pure-play focus.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The biggest specific risk is still regulatory. For CSL, carlisle's end markets are cyclical: commercial and residential construction activity is sensitive to interest rates, credit availability, and the broader economy, and a downturn in construction spending would pressure volumes.
CERS or CSL: which should you pick?
If the story you believe is CERS's (Platelet and plasma kit volume), CERS is the more direct way to own it; if it is CSL's (Commercial re-roofing replacement cycle), CSL is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CERS and CSL guides.
CERS vs CSL: the full fundamentals
CERS. At ~$1.90 a share on November 20, 2026, Cerus is valued at roughly 1.7 times trailing revenue, a low multiple next to many medical device peers, which reflects its history of losses, growth near 10% and margins in the low 50s. The company is close to breakeven, with positive adjusted EBITDA of ~$5.7M in Q3 2026 and a GAAP loss of only ~$0.6M, but trailing earnings are still negative, so a trailing P/E is not meaningful and the forward P/E of ~127x rests on a tiny expected profit. The four analysts tracked by Yahoo Finance have a mean price target of ~$5.12, far above the current price, which shows how much of the red blood cell outcome the market is still discounting.
CSL. Carlisle now trades near 22x trailing earnings and about 16x forward, up from 19x and 14x in October as the shares rose about 11% over the past month despite a Q3 margin squeeze. Investors still focus on adjusted EBITDA margin (about 23.8% in Q3), free cash flow (about $582 million trailing) and the pace of buybacks more than raw revenue growth, which swings with weather and construction cycles. Analysts expect about $21.04 of EPS for 2026 and about $24.07 for 2027, with fourth-quarter consensus near $4.45 on about $1.22 billion of revenue.
Headline figures (approximate, November 2026): CERS shows revenue (ttm) ~$227M (latest quarter up ~10% yoy), 2026 product revenue guidance ~$229M to $231M (reiterated), market cap ~$385M, price / sales (ttm) ~1.7x; CSL shows revenue (ttm) ~$5.2 billion, revenue growth (q3 2026, yoy) ~8.6% (organic ~8.8%), q3 2026 adjusted eps ~$5.92 vs ~$5.90 consensus, margins (ttm gross / operating / net) ~35% / ~20% / ~14%.
The bottom line: CERS vs CSL
CERS and CSL are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined CERS and CSL exposure against your real portfolio. It is not an investment adviser.
Wondering how CERS or CSL fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Cerus Corporation
Ask Walnut's AI anything about CERS and see how it fits what you own.
FAQ
What is the difference between CERS and CSL?
+
Cerus Corporation, based in Concord, California, makes the INTERCEPT Blood System, a technology that treats donated blood components so that viruses, bacteria, parasites and white blood cells cannot replicate. Carlisle Companies Incorporated (NYSE: CSL) is a diversified manufacturer that, after years of portfolio reshaping, has become a focused supplier of building-envelope products that make commercial and residential buildings more energy efficient. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is CERS or CSL the better stock?
+
Neither is universally better. CSL is the larger incumbent; CERS is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, CERS or CSL?
+
On forward P/E (as of November 2026), CERS trades at 127.33x and CSL at 16.01x, so CSL is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both CERS and CSL?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of CERS vs CSL?
+
CERS: The biggest specific risk is still regulatory. RedeS met its primary endpoint, but the FDA has not reviewed the final study report, the trial found treatment-specific antibodies in 2.2% of INTERCEPT patients, and Cerus has not said when it will file. The red cell program has a history of delays, including a European CE Mark review that ended without approval in 2024, so a slow or demanding review would push the main growth catalyst further out. Second, margins remain under pressure: product gross margin was ~52.4% in Q3 2026 against ~53.4% a year earlier, partly because most sales are in euros and partly because of input cost inflation, and currency swings can cut either direction. Third, the balance sheet is thin for a company still funding late-stage development: cash and short-term investments were ~$57M at September 30, 2026, against ~$75M of debt. If losses widen or approval work gets expensive, Cerus could raise equity at a share price below $2, diluting holders. Fourth, customer concentration is real, since a handful of large blood center networks and national blood services account for a large share of sales. Finally, competing approaches such as cold-stored platelets, rapid bacterial testing and rival pathogen reduction systems could slow adoption, and BARDA funding depends on US government budgets. The share price itself has been volatile, falling about 30% in the three months to November 20, 2026. CSL: Carlisle's end markets are cyclical: commercial and residential construction activity is sensitive to interest rates, credit availability, and the broader economy, and a downturn in construction spending would pressure volumes. Revenue can swing on weather, as seen in Q1 2026 when unfavorable winter conditions limited contractors' days on the roof and helped push revenue down about 4% year over year. The business is exposed to raw-material and energy cost inflation (chemicals, membranes, insulation feedstocks), which in Q3 2026 cut operating margin to about 20% from 21.8% and delayed price-cost parity by a quarter, and to destocking or restocking cycles in its distribution channel that can amplify demand swings. Competition in single-ply roofing is intense, with large rivals such as Holcim (owner of Firestone and Duro-Last), GAF, and Johns Manville. Finally, much of Carlisle's growth story depends on continued margin expansion and disciplined capital allocation, so any slippage in pricing power or a misstep in M&A could weigh on the shares. The balance sheet carries about $2.9 billion of debt against about $547 million of cash, and debt-funded buybacks leave less cushion if a construction slowdown arrives; the PermaTherm deal adds integration risk, and the shares have also traded as low as about $295 in the past year.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell CERS or CSL; figures are approximate and dated (as of November 2026). Verify current data before investing.